Clinical Trial

Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)

Study acronym: DEXAML-02
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 29, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Recent preclinical and clinical data strongly suggested that dexamethasone could improve the activity of intensive chemotherapy in AML. In this study, the FILO study group will assess the impact of adding dexamethasone to both induction and consolidation therapy in older AML patients with intermediate or favorable risk.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-07-31; most recent amendment 2024-10-25.
Status change: Recruiting → Active, Not Recruiting 2020-05-15
Status change: Not Yet Recruiting → Recruiting 2018-10-23
Trial Details
NCT Number NCT03609060
Lead Sponsor French Innovative Leukemia Organisation
Conditions Acute Myeloid Leukemia
Enrollment 120 participants
Start Date 2018-08-24
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-29